Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
A scientifically invalid study by financially compromised psychiatrists is but industy’s latest effort to rehabilitate SSRI antidepressants in the wake of public disclosure that these drugs DOUBLED the risk of suicidal acts.
This young child represents millions of children in the United States who are falling prey to licensed, but irresponsible prescribers of toxic drugs.
“Catastrophic side effects may be rare, but they become predictable when we treat so many children with so many drugs.”
The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign." Its goal is to get one million people to stop and reevaluate the medications they are taking.
“To me one of the miracle of children’s brains is that we don’t see more harm from these treatments.”
News headlines in the Boston area report about the death of four year old
Rebecca Riley, the latest child casualty of prescribed psychotropic drugs.
These illegal practices are the secret behind this toxic drug–Zyprexa– becoming a blockbuster seller.
In essence FDA proposals merely change the seating arrangement on the deck of the sinking Titanic. Eli Lilly announced that it intends to seek FDA approval for a long-lasting injectable form of Zyprexa (taken once a month).
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?